简介:目的:对常用的国外光盘文摘数据库进行药学文献覆盖率等比较研究,找出药学文的收载特点.方法:对德温特药学文摘(Derwentdrugfiles,DDF)、荷兰医学文摘(Embase,EMB)、国际药学文摘(Internationalpharmacyabstracts,IPA)、美国医学索引(Medline,MED)等数据库分别进行高引用率期刊的收载情况、特定课题检索,各数据库检索结果逐一比较.检索时段为1997~1999年.结果:从医院药学的六个学科领域汇总统计出引用频率高的期刊90种(覆盖了所有引文的95%).90种期刊在DDF、EMB、IPA、MED四个数据库中分别收载了60、78、37、78种,4个数据库均收载的期刊有23种.IPA收载的品种少,但有4种期刊独家收载.不同文摘数据库中收载同一期刊的论文数量不相同.特定课题检索中,有两个课题检索到4个数据库都收载的文献,大部分课题的文献被3个数据库同时收载.不同数据库收载的文献有一定差异.结论:各数据库收载文献是有选择的,应查阅所有的文摘数据库,才能保证药学信息的检全率.
简介:PURPOSE:ResistancetotemozolomidechemotherapyispartlymediatedbyO^6-methylguanine-DNAmethlytransferase(MGMT).ProtractedtreatmentwithtemozolomidepotentiallyovercomesMGMTresistanceandimprovesoutcome.WeconductedaphaseIIstudyofprotracteddailytemozolomideinadultswithlow-gradegliomas.EXPERIMENTALDESIGN:PatientswithnewlydiagnosedoligodendrogliomaoroligoastrocytomawithaMIB-1indexof〉5%orrecurrentlow-gradegliomasreceivedtemozolomide(75mg/m^2/dayin11-weekcyclesof7weekson/4weeksoff).Treatmentcontinuedforatotalofsixcyclesoruntiltumorprogressionorunacceptabletoxicity.Primaryendpointwasbestoverallresponserate;secondaryendpointswereprogression-freesurvival,overallsurvival,andtoxicity.
简介:BACKGROUND:In2004,arandomisedphaseⅢtrialbytheEuropeanOrganisationforResearchandTreatmentofCancer(EORTC)andNationalCancerInstituteofCanadaClinicalTrialsGroup(NCIC)reportedimprovedmedianand2-yearsurvivalforpatientswithglioblastomatreatedwithconcomitantandadjuvanttemozolomideandradiotherapy.We'reportthefinalresultswithamedianfollow-upofmorethan5years.METHODS:Adultpatientswithnewlydiagnosedglioblastomawererandomlyassignedtoreceiveeitherstandardradiotherapyoridenticalradiotherapywithconcomitanttemozolomidefollowedbyuptosixcyclesofadjuvanttemozolomide.
简介:PURPOSE:Toevaluatethetoxicityandresponserateofbortezomibwithconcurrentradiotherapyandtemozolomideinthetreatmentofpatientswithcentralnervoussystemmalignancies.PATIENTSANDMETHODS:Thisopen-label,dose-escalation,PhaseⅠclinicalstudyevaluatedthesafetyofthreedoselevelsofintravenouslyadministeredbortezomib(0.7,1.0,and1.3mg/m(2)/dose)onDays1,4,8,and11ofa21-daycycle,inadditiontoconcurrentradiotherapyandtemozolomideatadailydoseof75mg/m(2)startingonDay1.Theprimaryendpointwasdose-limitingtoxicity,definedasanyGrade4-5toxicityorGrade3toxicitydirectlyat-tr/butabletoprotocoltreatment,requiringhospitalizationand/orradiotherapyinterruption.
简介:研发前言Rockwell科学公司开发高温SiC电机传动系统Rockwell科学公司与美国空军研究实验室将共同开发高效、高温和小型的电机传动系统,应用于飞机和太空船。该项目主要开发基于SiC(碳化硅半导体)开关的磁阻电机传动,检验在200℃工作的容错电气传动装置。开发这种能在几乎无冷却的恶劣环境下工作的电机传动系统,关键是研发高温SiC开关,封装,控制电子学和电机。这些装置将显著降低电力电子的尺寸和重量。
简介:PURPOSE:ThisphaseⅡtrialwasdesignedtodefinetheroleofO^6-benzylguanine(O^6-BG)inrestoringtemozolomidesensitivityinpatientswithrecurrentorprogressive,temozolomidc-resistantmalignantgliomaandtoevaluatethesafetyofadministeringO^6-BGincombinationwithtemozolomide.PATIENTSANDMETHODS:Patientswereaccruedintotwoindependentstrataonthebasisofhistology:glioblastomamultifonne(GBM)andaanaplasticglioma.BothtemozolomideandO6-BGwereadministeredonday1ofa28-daytreatmentcycle.Patientswereadministereda1-hourO^6-BGinfusionatadoseof120mg/m^2followedimmediatelybya48-hourinfusionatadoseof30mg/m^2/d.
简介:PURPOSE:Toevaluatesingle-agentactivityofbevacizumabinpatientswithrecurrentglioblastoma.PATIENTSANDMETH-ODS:Patientswithrecurrentglioblastomaweretreatedwithbevacizumab10mg/kgevery2weeks.Aftertumorprogression,patientswereimmediatelytreatedwithbevacizumabincombinationwithirinotecan340mg/m^2or125mg/m^2every2weeks,dependingonuseofenzyme-inducingantiepilepticdrugs.Completepatientevaluationswererepeatedevery4weeks.RESULTS:Forty-eightheavilypretreatedpatientswereaccruedtothisstudy.Thromboembolicevents(12.5%),hypertension(12.5%),hypophosphatemia(6%),andthrombocytopenia(6%)werethemostcommondrug-associatedadverseevents.Sixpatients(12.5%)wereremovedfromstudyfordrug-associatedtoxicity(fivethromboembolicevents,onebowelperforation).
简介:PURPOSE:Fotemustineisanitrosoureacompoundusedforthetreatmentofmalignantgliomas,especiallyinFrance.Recently,anEORTC-NCICstudyhasshownthataconcomitantcombinationofradiotherapyplustemozolomide(anoralcytotoxicdrug)improvedsurvivalinglioblastomapatients.Wesetouttotestaconcurrentcombinationofradiotherapyandfotemustinefornewlymalignantgliomas.
简介:BACKGROUND:SupratentorialPNET(sPNET)arerareCNStumorsofembryonaloriginarisinginchildrenandadults.Thetreat-mentofsPNETforallagegroupsatourcancercenterhasbeenbasedonthemanagementofmedulloblastoma(MB),involvingneurosurgicaldebulkingfollowedbyeranio-spinalirradiation(CS1)andsystemicchemotherapy.METHODS:MedicalrecordswerereviewedtogatherdemographicandclinicaldataaboutallembryonalCNStumorsinchildrenandadultsfrom2001to2007.Tumorpathology,clinicalmanagementandsurvivaldatawerealsoassessed,particularlyasregardsthosepatientswhoreceivedthePackerchemotherapyregimenforeithersPNETorMB.
简介:Humanglioblastomas(GBM)arethoughttobeinitiatedbygliomastem-likecells(GSLCs).GSLCsalsoparticipateintumorneovascularizationbytransdifferentiatingintovascularendothelialcells.Here,wereportacriticalroleofGSLCsintheformationofvasculogenicmimicry(VM),whichdefineschannelslinedbytumorcellstosupplynutrientstoearlygrowingtumorsandtumor
简介:Glioblastomaisoneofthemostangiogenichumantumorsandcharacterizedbymicrovascularproliferations.Abetterunderstandingofglioblastomavasculatureisneededtooptimizeanti-angiogenictherapythathasshownapromisingbutincompleteefficacy.Thepresentstudyexamined48glioblastomasbyCD34endothelialmarkerperiodicacid-Schiff(PAS)dualstainingandfoundnon-endothelialcell-linedblood